Ozmosi | Sarcolysin Drug Profile

Product Description

St. Jude Children's Research Hospital is developing sarcolysin as an anticancer medicine. It is a type of chemotherapy that works by slowing or stopping growth of cancer cells. It may be used to help prepare patients for hematopoietic cell transplant. (Sourced from: https://together.stjude.org/en-us/diagnosis-treatment/medicines-list/melphalan.html)

Mechanisms of Action: Alkylating Agent

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: India | Russia

Approved Indications: None

Known Adverse Events: None

Company: City of Hope Medical Center
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
ACTRN12622000300774p	2006-7041-83/hah	N/A	Not yet recruiting	Chronic Cough	2023-10-31
NCT01769911	NCI-2012-03168	N/A	Withdrawn	AIDS-Related Lymphoma\|T-Cell Cutaneous Lymphoma\|Diffuse Large B-Cell Lymphoma\|Extranodal NK-T-Cell Lymphoma\|Follicular Lymphoma\|Plasmablastic Lymphoma\|Large Granular Lymphocytic Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Intraocular Lymphoma\|Chronic Lymphoid Leukemia\|Burkitt Lymphoma\|Lymphocytic Chronic B-Cell Leukemia\|Hairy Cell Leukemia\|Leukemia, Plasma Cell\|Mycosis Fungoides\|Large-Cell Anaplastic Lymphoma\|Immunoblastic Lymphadenopathy\|T-Cell Peripheral Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Sezary Syndrome\|Lymphomatoid Granulomatosis\|Mantle-Cell Lymphoma\|Waldenstrom Macroglobulinemia\|Lymphoma, Non-Hodgkin\|B-Cell Marginal Zone Lymphoma\|Adult T-Cell Leukemia-Lymphoma\|Large-Cell Immunoblastic Lymphoma	2019-02-01	2024-11-27	Primary Endpoints
NCT02960646	NCI-2016-01915	P1	Completed	Anemia, Aplastic\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Myelomonocytic Leukemia\|Lymphoma, Non-Hodgkin\|Chronic Myelomonocytic Leukemia\|Myelodysplastic Syndrome\|Myeloproliferative Disorders\|Acute Monocytic Leukemia\|Blast Crisis\|Lymphoma, B-Cell\|Acute Myeloid Leukemia\|Multiple Myeloma\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Acute Lymphoid Leukemia\|Chronic Myeloid Leukemia\|Juvenile Myelomonocytic Leukemia,\|Chronic Lymphoid Leukemia\|Leukemia, Plasma Cell\|Lymphocytic Chronic B-Cell Leukemia\|Preleukemia	2023-02-13	2023-02-18	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT01619761	NCI-2012-02071	P1	Unknown status	Acute Lymphoid Leukemia\|Chronic Myeloid Leukemia\|Lymphoma, Non-Hodgkin\|Acute Myeloid Leukemia\|Myeloid, Accelerated Leukemia\|Lymphocytic Chronic B-Cell Leukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Lymphoma, B-Cell\|Multiple Myeloma\|Preleukemia\|Leukemia, Plasma Cell\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Myelodysplastic Syndrome\|Biphenotypic Acute Leukemia\|Chronic Lymphoid Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2021-11-01	2022-02-02	Primary Endpoints\|Treatments\|Trial Status
NCT01625351	RADIANT	P1	Completed	Lymphoma\|Gastrointestinal Cancer\|Melanoma\|Rhabdoid Tumor\|Clear Cell Sarcoma\|Clear Cell Adenocarcinoma\|Wilms Tumor\|Neuroblastoma\|Renal Cell Carcinoma\|Sarcoma, Ewing\|Rhabdomyosarcoma\|Adenomyoepithelioma	2020-02-10	2020-10-20	Primary Endpoints
NCT02130869	ASCIST	P1	Completed	Neuroblastoma\|Lymphoma	2017-12-20	2024-11-27	Primary Endpoints
NCT02472392	Ewing/Allo	P1	Completed	Sarcoma, Ewing	2016-12-01	2019-03-20	Treatments
NCT05031897	21D.466	P2	Recruiting	Chronic Lymphoid Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia\|Acute Monocytic Leukemia\|Acute Myelomonocytic Leukemia\|Anemia, Aplastic\|Myelodysplastic Syndrome\|Myelofibrosis\|Polycythemia Vera\|Thrombocythemia, Essential\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Acute Myeloid Leukemia\|Adult T-Cell Leukemia-Lymphoma\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Chronic Myeloid Leukemia\|Lymphocytic Chronic B-Cell Leukemia\|Multiple Myeloma\|Lymphoma, B-Cell\|Lymphoma, Non-Hodgkin\|Chronic Myelomonocytic Leukemia	2032-04-01	2025-10-31	Primary Endpoints
NCT05564390	MYELOMATCH	P2	Recruiting	Myelodysplastic Syndrome\|Acute Myeloid Leukemia\|Myeloproliferative Disorders	2029-05-15	2026-03-05	Primary Endpoints
NCT02727803	NCI-2016-00584	P2	Recruiting	Biphenotypic Acute Leukemia\|Chronic Lymphoid Leukemia\|Acute Myelomonocytic Leukemia\|B-Cell Leukemia\|Myelodysplastic Syndrome\|Multiple Myeloma\|Acute Myeloid Leukemia\|Juvenile Myelomonocytic Leukemia,\|Anemia, Refractory, with Excess of Blasts\|Lymphoma, Non-Hodgkin\|Leukemia, Plasma Cell\|Lymphoma, B-Cell\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Myelodysplastic-Myeloproliferative Diseases\|Chronic Myelomonocytic Leukemia\|Chronic Myeloid Leukemia\|Acute Lymphoid Leukemia\|Preleukemia\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Myeloid, Accelerated Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Acute Monocytic Leukemia\|Myeloproliferative Disorders	2027-05-31	2025-05-10	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT00692939	STUDY19100005	P2	Recruiting	Crohn Disease	2026-12-01	2025-12-16	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments
NCT02700841	0669-19-FB	P2	Terminated	Multiple Myeloma	2022-12-21	2023-08-30	Primary Endpoints\|Start Date\|Treatments
NCT03096782	NCI-2018-01236	P2	Completed	Myeloid, Accelerated Leukemia\|Acute Monocytic Leukemia\|Chronic Myeloid Leukemia\|Anemia, Refractory, with Excess of Blasts\|Juvenile Myelomonocytic Leukemia,\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Preleukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Lymphocytic Chronic B-Cell Leukemia\|Chronic Lymphoid Leukemia\|Myelodysplastic Syndrome\|Acute Lymphoid Leukemia\|Hodgkin Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Histiocytosis, Langerhans-Cell\|Biphenotypic Acute Leukemia\|Acute Myeloid Leukemia\|Lymphoma, Non-Hodgkin\|Chronic Myelomonocytic Leukemia\|Lymphoma, B-Cell\|Acute Myelomonocytic Leukemia	2022-09-20	2023-06-30	Primary Endpoints
NCT01904136	NCI-2013-02183	P2	Completed	Blast Crisis\|Acute Myeloid Leukemia\|Preleukemia\|Chronic Myeloid Leukemia\|Myeloid, Accelerated Leukemia\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Myelodysplastic Syndrome	2022-02-28	2024-01-18
NCT01857934	Neuroblastoma Protocol 2012	P2	Active, not recruiting	Neuroblastoma	2021-10-21	2024-11-27	Primary Endpoints\|Treatments
NCT01807611	HAPNK1	P2	Completed	Leukemia\|Lymphoma	2021-08-27	2022-11-01	Patient Enrollment\|Primary Endpoints\|Treatments
NCT02797470	AMC-097	P2	Active, not recruiting	Large-Cell Immunoblastic Lymphoma\|Mantle-Cell Lymphoma\|Lymphoma, Non-Hodgkin\|Follicular Lymphoma\|Burkitt Lymphoma\|HIV Infections\|T-Cell Lymphoma\|Plasmablastic Lymphoma	2021-05-13	2024-11-27	Primary Endpoints\|Treatments
NCT04205240	OSU-19190	P2	Terminated	Multiple Myeloma	2021-05-08	2023-09-29	Primary Endpoints
NCT02756572	NCI-2016-00477	P2	Completed	Acute Myeloid Leukemia\|Juvenile Myelomonocytic Leukemia,\|Chronic Myeloid Leukemia\|Acute Myelomonocytic Leukemia\|Acute Monocytic Leukemia\|Chronic Myelomonocytic Leukemia\|Anemia, Refractory, with Excess of Blasts\|Preleukemia\|Myelodysplastic Syndrome	2020-03-01	2024-11-27	Primary Endpoints\|Treatments
NCT01008462	NCI-2009-01334	P2	Completed	Prolymphocytic B-Cell Leukemia\|Chronic Lymphoid Leukemia\|T-Cell Lymphoma\|Waldenstrom Macroglobulinemia\|Lymphoma, B-Cell\|Multiple Myeloma\|Leukemia, Plasma Cell\|Prolymphocytic T-Cell Leukemia\|Lymphocytic Chronic B-Cell Leukemia\|Lymphoma, Non-Hodgkin\|Prolymphocytic Leukemia	2018-06-30	2024-11-27	Primary Endpoints
NCT01531244	11-X335	P2	Withdrawn	Melanoma	2016-02-01	2024-06-26	Primary Endpoints
NCT02259348	REFNK1	P2	Terminated	Chronic Myelomonocytic Leukemia\|Acute Myelomonocytic Leukemia\|Chronic Myeloid Leukemia\|Preleukemia\|Juvenile Myelomonocytic Leukemia,\|Sarcoma, Myeloid\|Acute Monocytic Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Lymphoma, Non-Hodgkin\|Acute Lymphoid Leukemia\|Acute Myeloid Leukemia\|Chronic Lymphoid Leukemia\|Myelodysplastic Syndrome\|Myelogenous, Chronic, BCR-ABL Positive Leukemia	2015-04-01	2019-03-20
NCT06172296	NCI-2023-08530	P3	Recruiting	Ganglioneuroblastoma	2029-12-31	2025-08-27	Primary Endpoints\|Treatments
NCT05457556	ASCT2031	P3	Active, not recruiting	Acute Myeloid Leukemia\|Myelodysplastic Syndrome\|Acute Lymphoid Leukemia\|Preleukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma	2026-06-30	2025-05-06	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT00567567	ANBL0532	P3	Completed	Neuroblastoma	2015-02-27	2024-11-27	Primary Endpoints

Recent News Events

Date	Type	Title
05/15/2024	PubMed	Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
05/10/2024	PubMed	Current status of bispecific antibodies and CAR-T therapies in multiple myeloma.
04/27/2024	PubMed	Dissecting the Puzzling Roles of FAM46C: A Multifaceted Pan-Cancer Tumour Suppressor with Increasing Clinical Relevance.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Sarcolysin

Alternative Names: sarcolysin Clinical Status: Inactive Latest Update: 2026-03-04 Latest Update Note: Clinical Trial Update